Tygacil by the Tail? Tetraphase IPO: $86M for New Antibiotics
By Randy Osborne
Tuesday, February 12, 2013
Looking to bolster its planned Phase III trial with TP-434 (eravacycline) for complicated intra-abdominal infections, Tetraphase Pharmaceuticals Inc. filed for an initial public offering that would raise up to $86.2 million, though neither the targeted number of shares nor the price of each was disclosed.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.